PATENT CLAIM ANALYSIS

Application Number: 16000557
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-05
Patent Classification: ["424", "094600"]

Abstract:
The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease), In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.

Claim (Index 50):
The stable formulation of  claim 48 , wherein less than 1% of the arylsulfatase A (ASA) protein exists in aggregated form.

Metadata:
- Claim Count in Document: 55.0
- Percentile: 94.0
- Lexical Diversity: 1.37931
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15684568', '13168963', '15016141', '13168966', '13974457']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7532149839330895
- 35 USC 102 Novelty (BERT): 0.5288487975992273
- Combined Prediction Score: 0.7307783652997033
- Mean Citation Score: 281.973274
- Max Citation Score: 331.15982
- Similarity Product: 197.09507455222493

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test